{
  "docId": "019de075-d6ea-7495-b63c-e64074d45b72",
  "docSlug": "3f99bbe59467be363a98d21e99cb078a",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 56,
  "pageCount": 58,
  "prevPage": 55,
  "nextPage": 57,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/56",
  "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72",
  "deckJsonHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72.json",
  "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-56",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.6,
        "x": 0.02,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: Berdeja JG, et al. Lancet. 2021; Frigault MJ, et al. Blood Adv. 2023; Munshi NC, et al. N Engl J Med. 2021; Asherie N, et al. Haematologica. 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d20e703-f232-4df1-a7cf-61ee502e942a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.96,
        "x": 0.02,
        "y": 0.315
      },
      "kind": "table",
      "text": "Comparison of NXC-201, Abecma, Carvykti, and CART-ddBCMA across lymphodepletion regimen, frequency, and infusion timing.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0f1b76c-11bf-458f-8356-3e946a9d20dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.27,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "Preconditioning Regimens",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "578190f1-123f-47bc-9d84-8158ec3f617b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "37874ca1-125b-4870-8c17-54b16d1d28ef",
      "evidence": "Comparison of NXC-201, Abecma, Carvykti, and CART-ddBCMA across lymphodepletion regimen, frequency, and infusion timing.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 58,
      "from": 46,
      "beatId": "4e07e972-cafc-486f-912e-2418cf212a13",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The deck concludes with a call to action and future plans",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}